Importantly, we demonstrated that DNA damaging cancer therapies up-regulated BCL6 expression in vitro and in an intra-cranial tumor model in vivo, and that blockade of BCL6 enhanced the efficacy of those therapies. The gene discussed is BCL6; the disease is neoplasm.